Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial

Documenti analoghi

• Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial
  di: Eun‐Gyoung Hong, et al.
  Pubblicazione: (2025)
• A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
  di: Tae Seo Sohn, et al.
  Pubblicazione: (2024)
• Effect of positive psychological capital on burnout in public hospital nurses: Mediating effect of compassion fatigue is greater than compassion satisfaction
  di: Sin Ah Kim, et al.
  Pubblicazione: (2024)
• Estimating the 15th‐Century Potential Habitats of Endangered Mammals on the Korean Peninsula: Implications for Restoration
  di: Dabin Kim, et al.
  Pubblicazione: (2025)
• A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
  di: Soo Lim, et al.
  Pubblicazione: (2024)